Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968 [PMID: 25152600 DOI: 10.3748/wjg.v20.i31.10960]
Corresponding Author of This Article
Lei Song, MS, Department of Medical Oncology, the Second Hospital of Dalian Medical University, Zhongshan Road 467, Dalian 116023, Liaoning Province, China. songlei_1975@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 21, 2014; 20(31): 10960-10968 Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10960
Table 1 Baseline characteristics
Total
CPT-11
GEM
DDP+5-FU
P value
(n = 107)
(n = 24)
(n = 24)
(n = 59)
OS
PFS
Mean age ± SD (yr)
57.0 ± 11.0
61.0 ± 8.7
57.5 ± 12.4
56.0 ± 11.4
Sex (M:F)
95:12
22:2
24:0
49:10
HBV
Absent/Present
26/81
7/17
6/18
13/46
0.583
0.734
Cirrhosis of the liver
Absent/Present
45/62
13/11
6/18
26/33
0.003
0.011
Tumor maximal diameter (cm)
7.8 ± 4.1
8.0 ± 3.9
7.7 ± 4.1
7.4 ± 4.2
≤ 5/> 5
30/77
4/20
5/19
21/38
0.361
0.165
Pathological T
T1/T2/T3/T4
8/32/50/17
3/8/10/3
0/9/10/5
5/15/30/9
0.070
0.052
Pathological Stage
I/II/III/IV
7/26/57/17
3/6/10/5
0/6/13/5
4/14/34/7
0.013
0.022
TACE Sessions
≤ 2/> 2
73/34
8/16
18/6
47/12
0.001
0.009
Initial AFP (ng/dL)
≤ 400/> 400
59/48
18/6
11/13
16/43
0.095
0.157
Number of Tumor Single/Multiple
57/50
12/12
13/11
32/27
0.017
0.039
Vascular invasion
Absent/Present
74/33
18/6
15/9
41/18
0.014
0.090
Child-Pugh
A/B
98/9
20/4
23/1
55/4
0.746
0.930
BCLC Stage
A/B/C
15/59/33
2/16/6
1/14/9
12/29/18
0.005
0.006
CLIP Score
≤ 2/> 2
77/20
20/4
18/6
39/20
0.013
0.013
MELD Score
≤ 6/> 6
74/33
17/7
16/8
41/18
0.914
0.610
ALB (g/L)
≤ 40/> 40
49/58
9/15
7/17
33/26
0.033
0.073
TB (μmol/L)
≤ 17/> 17
55/52
14/10
12/12
29/30
0.440
0.808
AST (U/L)
≤ 40/> 40
23/84
8/16
8/16
7/52
0.947
0.958
ALT (U/L)
≤ 40/> 40
32/75
11/13
8/16
13/46
0.456
0.522
Lipiodol (mL)
≤ 10/> 10
62/45
11/13
15/9
36/32
0.997
0.369
Table 2 Univariate and multivariate analysis for the factors that influence tumor progression
Factors
Univariate (P value)
Multivariate (P value)
Exp(B)
95%CI
Cirrhosis of the liver
Absent/Present
0.025
0.928
1.070
0.242-4.729
Pathological stage
I/II/III/IV
0.022
0.021
0.643
0.442-0.936
TACE Sessions
≤ 2/> 2
0.009
0.083
1.272
0.969-1.670
BCLC Stage
A/B/C
0.006
0.666
1.241
0.465-3.316
Number of Tumor
Single/Multiple
0.039
0.734
0.839
0.305-2.309
CLIP Score
≤ 2/> 2
0.013
0.466
0.822
0.485-1.392
Chemotherapy agent
CPT-11/GEM/Doxorubicin
0.020
0.648
0.869
0.474-1.591
PS score
1/2/2000
0.029
0.032
0.095
0.011-0.818
Table 3 Univariate and multivariate analysis for the factors influencing survival rate
Factors
Univariate (P value)
Multivariate (P value)
Exp(B)
95%CI
Cirrhosis of the liver
Absent/Present
0.003
0.083
5.114
0.806-32.436
Pathological Stage
I/II/III/IV
0.013
0.012
0.485
0.276-0.851
TACE Sessions
≤ 2/> 2
0.001
0.001
1.964
1.311-2.942
BCLC Stage
A/B/C
0.005
0.061
0.183
0.031-1.078
Number of Tumor
Single/Multiple
0.017
0.460
1.651
0.437-6.235
CLIP Score
≤ 2/> 2
0.013
0.982
0.992
0.496-1.985
Chemotherapy agent
CPT-11/GEM/Doxorubicin
0.004
0.019
0.407
0.192-0.863
ALB (g/L)
≤ 40/> 40
0.033
0.030
0.834
0.709-0.982
Table 4 Treatment-related toxicity
Grade I/II/III/IV
GEM
CPT-11
Doxorubicin
Aminotransferase elevation
2/4/2/0
4/2/0/0
7/2/1/0
Hyperbilirubinemia
1/0/0/0
1/0/0/0
2/0/0/0
Gastrointestinal toxicity
1/0/0/0
2/0/0/0
0/1/0/0
Post-embolization symptom
3/2/0/0
3/3/0/0
7/5/0/0
Bone marrow inhibition
4/5/3/2
2/1/2/1
8/5/4/0
Diarrhea
0/0/0/0
1/1/0/0
0/0/0/0
Citation: Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968